Updated:
Mirum Pharmaceuticals
Mirum Pharmaceuticals was incorporated in November 2018 in Foster City, California, to acquire and develop a therapy for Alagille syndrome that had been...
Mirum Pharmaceuticals
Mirum Pharmaceuticals was incorporated in November 2018 in Foster City, California, to acquire and develop a therapy for Alagille syndrome that had been shelved by a larger organization. The company was founded by leaders with deep rare-disease and biotech-building experience, who recognized the scientific opportunity and the urgency within the patient community. The therapy became LIVMARLI, approved by the FDA for cholestatic pruritus in Alagille syndrome and later for progressive familial intrahepatic cholestasis (PFIC). Mirum now sells three approved medicines globally and runs clinical programs targeting additional rare liver diseases. Its pipeline covers conditions such as biliary atresia and other cholestatic disorders, with geography spanning North America and Europe (per the firm's website, accessed June 2025). The company has not disclosed total capital raised, AUM, or the number of employees. In May 2025, Mirum announced new data from its rare liver disease programs at the EASL International Liver Congress 2026 (per company press release, May 2025). Adjacent vehicles or philanthropic arms are not publicly identified. Mirum's structure is that of a publicly traded biopharmaceutical company, not a traditional family office or asset manager. Its mandate is purely therapeutic development for high-need rare disease populations, executed through internal R&D and regulatory strategy. The firm's governance follows public-company norms with a board of directors and executive leadership accountable to shareholders.
General information
Firm type
other
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Foster City
Corporate office
Foster City, CA, United States
Additional offices
Zug, Switzerland
Sector focus
Frequently asked questions
Who runs investment decisions at Mirum Pharmaceuticals?
Mirum Pharmaceuticals is a publicly traded biopharmaceutical company, not a family office or investment firm. Investment decisions are made by its executive leadership and board of directors, whose names are not disclosed in public sources accessible for this profile.
How does Mirum Pharmaceuticals source proprietary deal flow?
Mirum develops its pipeline internally and through business development. The company began with an in-licensed program that had been deprioritized by a larger organization, and has since built a portfolio of three approved medicines and clinical programs targeting rare liver diseases (per the firm, accessed June 2025).
Is Mirum Pharmaceuticals structured as a single family office or does it operate more like a venture firm?
Mirum Pharmaceuticals is a publicly traded biopharmaceutical company, listed on the Nasdaq under the ticker MIRM. It is not a family office or venture firm; it operates with a traditional corporate structure focused on drug development and commercialization.
Does Mirum Pharmaceuticals participate in fund commitments or only direct deals?
Mirum Pharmaceuticals does not make fund commitments or direct investments as a financial firm. It conducts research, development, and commercialization of therapies for rare diseases.
What investment stages does Mirum Pharmaceuticals typically target?
Mirum focuses on drug development from early-stage clinical trials through regulatory approval and commercialization. Its pipeline includes programs in various stages, from preclinical to approved therapies.
Where does the underlying wealth come from?
Mirum Pharmaceuticals is a publicly traded company, so its capital comes from equity and debt markets, not from a single wealth source. The firm does not disclose a family-office wealth origin.
Does Mirum Pharmaceuticals maintain philanthropic structures, and how are they separated?
Mirum Pharmaceuticals does not publicly disclose any philanthropic foundation or separate charitable entity. The firm operates as a for-profit biopharmaceutical company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: